Elekta AB (SE:EKTAB) Launches ABAS 2.0 Autosegmentation Software Used to Plan Radiation Therapy in Patients With Cancer
10/4/2010 9:57:54 AM
ATLANTA, Oct. 1 /PRNewswire/ -- Elekta recently launched ABAS (Atlas-based Autosegmentation) 2.0 software, which includes the Simultaneous Truth and Performance Level Estimation (STAPLE) algorithm to increase contouring accuracy. ABASconsidered the industry gold standard for autosegmentation accuracydeforms atlases of anatomy previously defined on a reference image onto a new patient image, creating a new structure set fit to the patient anatomy and enhancing planning efficiency.
"The STAPLE algorithm allows multiple atlases to be calculated against a single patient," says Randy Larson, ABAS product manager. "The benefit is increased accuracy because the user is achieving the best result for each contour based on multiple sources. ABAS 2.0 also uses a graphics processor unit [GPU], which increases contouring speed by up to 50 percent. In addition, this release includes an improved user interface featuring new tools and functionality, as well as full DICOM service, to enhance workflow and file maintenance."
With its deformable registration algorithms, ABAS saves physician and dosimetrist time by automatically contouring new image sets based on anatomy defined in the atlas. Users may further edit and refine the new image sets.
User-definable atlases allow clinicians to select an atlas that accurately reflects a given patient in a particular clinic. Atlases also can be patient-specific to account for change in size, shape or deformation during treatment. The algorithm completes multiple phases of refinement for increased accuracy.
- Improves efficiency, allowing for treatment of more patients
- Runs in the background and allows for batch processing
- Seamless workflow integration with multiple vendor compatibility
- Improves contouring consistency
"ABAS has been a useful tool to increase contouring efficiency, and also safetybecause ABAS standard contours ensure that important organs at risk are included," says Peter Levendag, M.D., Ph.D., professor and radiation oncologist, Erasmus MC-Daniel den Hoed Cancer Center (Rotterdam, the Netherlands). "As an educational tool, ABAS enables medical residents to be tested by comparing their manually segmented contours with the gold standard from the Atlas."
To learn more, visit www.elekta.com/ABAS.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.